NCT00779064View on ClinicalTrials.gov

BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (BAY59-7939)

10mg BID, Semi-sequential, dose escalation.

DRUG

Rivaroxaban (BAY59-7939)

20mg BID, Semi-sequential, dose escalation.

Trial Locations (12)

811-0213

Fukuoka

814-0180

Fukuoka

800-0057

Kitakyushu

807-0051

Koga

830-8577

Kurume

061-1134

Kitahiroshima

660-8511

Amagasaki

586-8521

Kawachi-Nagano

540-0006

Osaka

553-0003

Osaka

558-8558

Osaka

565-0871

Suita

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY